Review Article
Volume 13:4, 2023

Journal of Nephrology & Therapeutics

ISSN: 2161-0959 Open Access

Different Drug Level Monitoring in Hemodialysis: A Comprehensive Review

Teyfon Adam*

Department of Pathology, University Mahidol, Bangkok, Thailand

Abstract

Hemodialysis is a life-saving treatment for patients with End-Stage Renal Disease (ESRD) but presents challenges when managing medications due to altered pharmacokinetics and drug clearance. Monitoring drug levels in hemodialysis patients is crucial to ensure therapeutic efficacy and prevent adverse effects. This review aims to explore various methods and considerations for drug level monitoring in hemodialysis, highlighting the importance of individualized treatment approaches and potential areas for future research.

Keywords: Hemodialysis • Drug monitoring • Pharmacokinetics • Individualized treatment

Introduction

End-Stage Renal Disease (ESRD) necessitates renal replacement therapy, with hemodialysis being one of the most commonly utilized methods. Hemodialysis effectively removes waste products and excess fluids but also eliminates drugs from the patient's system, resulting in altered pharmacokinetics and potential treatment complications. To achieve optimal therapeutic outcomes, careful monitoring of drug levels becomes essential in hemodialysis patients. Hemodialysis is a life-saving renal replacement therapy used in patients with ESRD. However, managing medications in hemodialysis patients poses significant challenges due to altered pharmacokinetics and drug clearance during the dialysis process. As drugs are eliminated alongside waste products, achieving optimal therapeutic levels becomes crucial to ensure treatment efficacy and safety.

This comprehensive review delves into the various methods of drug level monitoring in hemodialysis patients, aiming to shed light on the importance of individualized treatment approaches. The altered pharmacokinetics, drug interactions, and dialysate composition further complicate drug administration during hemodialysis. By exploring key drugs and their monitoring considerations, healthcare professionals can tailor dosing regimens to mitigate adverse reactions and maintain therapeutic concentrations. The review also discusses innovative approaches like therapeutic drug monitoring, biomarkers, pharmacogenetic testing, and point-of-care testing, which offer promising avenues for precise drug management. Understanding the challenges and advancements in drug level monitoring within the context of hemodialysis is essential for improving patient care and treatment outcomes in this vulnerable population [1,2].

Literature Review

Challenges in drug administration during hemodialysis

Drug administration during hemodialysis presents unique challenges due to the altered pharmacokinetics and drug clearance observed in patients with End-Stage Renal Disease (ESRD) undergoing dialysis. These challenges can significantly impact the efficacy and safety of drug therapies, requiring careful consideration and individualized approaches. One of the primary challenges is the altered pharmacokinetics of drugs in hemodialysis patients. Changes in drug absorption, distribution, metabolism, and elimination occur as a result of impaired renal function and dialysis-induced alterations in blood flow and protein binding. This leads to unpredictable drug concentrations and necessitates close monitoring to maintain therapeutic levels.

Another significant concern is drug interactions with the dialysis process itself. Some medications may be adsorbed onto dialysis membranes, leading to reduced drug availability and inadequate therapy. Conversely, certain drugs may be incompletely cleared during dialysis, causing drug accumulation and potential toxicity [3]. The composition of the dialysate used during the hemodialysis procedure can also influence drug clearance. Variations in electrolyte concentrations and pH can affect drug diffusion, further complicating drug dosing and efficacy.

The timing of drug administration in relation to hemodialysis sessions requires careful planning. Drugs with short half-lives or those primarily cleared by the kidneys may require dose adjustments to avoid drug accumulation during or between dialysis treatments.

Drug administration during hemodialysis poses multiple challenges, including altered pharmacokinetics, drug interactions, dialysate composition, and timing of drug administration. To address these challenges effectively, healthcare professionals must adopt individualized treatment strategies, conduct regular drug level monitoring, and remain vigilant to prevent adverse reactions and optimize therapeutic outcomes for hemodialysis patients [4].

Methods of drug level monitoring in hemodialysis patients

Monitoring drug levels in hemodialysis patients is crucial to ensure optimal therapeutic outcomes and prevent potential adverse effects. Various methods are employed to assess drug concentrations in this population, each offering unique advantages and limitations [5].

Therapeutic Drug Monitoring (TDM): TDM involves measuring drug levels in patient blood samples at specific intervals to maintain drug concentrations within the therapeutic range. It helps individualize drug dosing, especially for drugs with narrow therapeutic windows or significant inter-patient variability.

Biomarkers: Some drugs exhibit complex pharmacokinetics in hemodialysis patients, making direct drug level monitoring challenging. In such cases, evaluating drug metabolites or surrogate markers may provide insights into drug efficacy and exposure.

***Address for Correspondence:** Teyfon Adam, Department of Pathology, University Mahidol, Bangkok, Thailand; E-mail: adam.teyfon@gmail.com*

Received: 13 June, 2023, Manuscript No. JNT-23-108736; **Editor Assigned:** 15 June, 2023, PreQC No. P-108736; **Reviewed:** 28 June, 2023, QC No. Q-108736; **Revised:** 04 July, 2023, Manuscript No. R-108736; **Published:** 11 July, 2023, DOI: 10.37421/2161-0959.2023.13.452

Pharmacogenetic testing: Genetic variations can significantly impact drug response and metabolism in hemodialysis patients. Pharmacogenetic testing identifies relevant genetic markers, enabling personalized drug selection and dosing adjustments.

Point-of-care testing: Rapid and convenient methods, such as handheld devices or immunoassays, allow real-time drug level assessments during hemodialysis sessions. These tools aid in quick decision-making for dose adjustments, especially in critical situations.

Imaging techniques: In some cases, imaging techniques like Positron Emission Tomography (PET) can help visualize drug distribution and accumulation in various organs, providing valuable insights into drug pharmacokinetics during hemodialysis.

Model-Based approaches: Pharmacokinetic modeling uses mathematical models to estimate drug concentrations and optimize dosing regimens for individual patients, taking into account their unique dialysis parameters. Overall, a combination of these methods is often required to achieve effective drug level monitoring in hemodialysis patients. Individualized drug dosing based on monitoring results and patient-specific factors can enhance treatment efficacy while minimizing the risk of adverse reactions in this vulnerable population.

Discussion

Key drugs and their monitoring considerations in hemodialysis

Hemodialysis patients often require multiple medications to manage various medical conditions. Monitoring drug levels in this population is essential to ensure therapeutic efficacy while avoiding drug-related complications. Here are some key drugs commonly prescribed to hemodialysis patients and their monitoring considerations:

Antibiotics

Vancomycin: Therapeutic Drug Monitoring (TDM) is crucial due to its narrow therapeutic range and potential nephrotoxicity.

Aminoglycosides: Regular drug level monitoring is essential to prevent toxicity, as these drugs are significantly cleared by hemodialysis.

Anticoagulants

Heparin: Regular monitoring of activated Partial Thromboplastin Time (aPTT) helps adjust dosing to maintain therapeutic anticoagulation.

Warfarin: International Normalized Ratio (INR) monitoring is necessary to optimize anticoagulation without increasing bleeding risk.

Antiepileptics

Phenytoin: TDM is recommended due to its nonlinear pharmacokinetics and high protein binding, which can be affected by uremia.

Carbamazepine: Monitoring drug levels helps prevent toxicity, especially during concurrent use of interacting medications.

Cardiovascular medications

Digoxin: Regular monitoring of serum digoxin levels is vital due to its narrow therapeutic window and potential for toxicity in ESRD.

Beta-blockers and ACE inhibitors: Dosing adjustments may be necessary, considering altered pharmacokinetics and drug clearance.

Monitoring considerations for these drugs also involve assessing drug interactions, as some medications may interfere with hemodialysis or influence drug metabolism. Pharmacogenetic testing and individualized dosing based on pharmacokinetic modeling can further optimize drug therapy in hemodialysis patients. Regular communication and coordination between nephrologists, pharmacists, and other healthcare providers are essential to ensure safe and effective drug management in this vulnerable population.

Individualized drug dosing in hemodialysis patients

Individualized drug dosing in hemodialysis patients is imperative to optimize therapeutic efficacy, prevent adverse effects, and ensure patient safety. Due to the altered pharmacokinetics and drug clearance in this population, standard dosing regimens may not be appropriate, necessitating tailored approaches.

Pharmacokinetic modeling: Mathematical models can estimate drug concentrations in hemodialysis patients based on their unique dialysis parameters, residual renal function, and other individual factors [6]. These models help calculate appropriate drug doses that maintain therapeutic levels during and between dialysis sessions.

Extended interval dosing: For drugs with significant renal clearance, such as certain antibiotics, adjusting the dosing interval while maintaining the total daily dose can prevent drug accumulation and toxicity. This approach compensates for drug removal during dialysis sessions.

Post-dialysis administration: Administering drugs after hemodialysis can help avoid drug removal during the session, ensuring adequate drug exposure during the interdialytic period.

Alternative routes of drug administration: For drugs predominantly cleared by the kidneys, alternative routes (e.g., transdermal, intramuscular) can be considered to bypass renal elimination pathways, minimizing the need for dose adjustments.

Therapeutic Drug Monitoring (TDM): Regular monitoring of drug levels allows healthcare providers to adjust dosing regimens according to individual patient responses, ensuring drugs remain within the therapeutic range.

Patient Characteristics: Factors such as age, weight, residual renal function, and coexisting medical conditions should be taken into account when determining drug dosages to achieve personalized treatment plans.

Adverse drug reactions in hemodialysis patients

Adverse Drug Reactions (ADRs) are a significant concern in hemodialysis patients due to their altered pharmacokinetics and drug clearance. These patients are more susceptible to ADRs, which can lead to severe consequences and compromise the efficacy of drug therapies.

Drugs with reduced renal clearance can accumulate in hemodialysis patients, leading to higher systemic exposure and an increased risk of toxicity. Medications with narrow therapeutic windows, such as digoxin and certain antibiotics, require careful monitoring to avoid toxic levels. Inadequate or excessive dialysis can impact drug removal during dialysis sessions. Hypo-dialysis may not effectively clear drugs, leading to drug accumulation, while hyper-dialysis can remove medications too rapidly [7], result in suboptimal therapeutic levels. Hemodialysis sessions can trigger various physiological changes, such as shifts in volume and electrolyte imbalances, which may alter drug metabolism and distribution, increasing the risk of ADRs. Hemodialysis patients often take multiple medications, leading to potential drug-drug interactions that can exacerbate ADRs or decrease drug efficacy.

To mitigate the risk of ADRs in hemodialysis patients, healthcare providers must adopt strategies such as Therapeutic Drug Monitoring (TDM) to adjust drug doses based on individual patient responses. Regular monitoring of drug levels, assessing drug interactions, and individualizing drug dosing based on pharmacokinetic considerations are essential components of managing drug therapy safely and effectively in this vulnerable population. A multidisciplinary approach involving nephrologists, pharmacists, and other healthcare professionals is crucial for minimizing ADRs and optimizing treatment outcomes in hemodialysis patients.

Conclusion

Drug level monitoring is indispensable in hemodialysis patients to ensure therapeutic efficacy and mitigate adverse reactions. Individualized drug dosing based on monitoring results and patient-specific factors is essential. Embracing emerging technologies and collaborative efforts among healthcare

professionals will drive continuous improvement in drug management for this vulnerable population.

Acknowledgement

Not applicable.

Conflict of Interest

There is no conflict of interest by author.

References

1. London, Gerard M. "Cardiovascular disease in chronic renal failure: Pathophysiologic aspects." *Semin Dial* 16 (2003): 85-94.
2. Nitta, Kosaku, Satoshi Iimuro, Enyu Imai and Seiichi Matsuo, et al. "Risk factors for increased left ventricular hypertrophy in patients with chronic kidney disease: Findings from the CKD-JAC study." *Clin Exp Nephrol* 23 (2019): 85-98.
3. Heidbreder, Ekkehart, Klaus Schafferhans and August Heidland. "Autonomic neuropathy in chronic renal insufficiency: Comparative analysis of diabetic and nondiabetic patients." *Nephron* 41 (1985): 50-56.
4. Sars, Benedict, Frank M. Van der Sande and Jeroen P. Kooman. "Intradialytic hypotension: Mechanisms and outcome." *Blood Purif* 49 (2020): 158-167.
5. Kovesdy, Csaba P., Kumar Sharma and Kamyar Kalantar-Zadeh. "Glycemic control in diabetic CKD patients: Where do we stand?" *Am J Kidney Dis* 52 (2008): 766-777.
6. Kovesdy, Csaba P., Jong C. Park and Kamyar Kalantar-Zadeh. "Glycemic control and burnt-out diabetes in ESRD." *Semin Dial* 23 (2010): 148-156.
7. Eloot, Sunny, Wim Van Biesen, Annemieke Dhondt and Rita De Smet, et al. "Impact of increasing haemodialysis frequency versus haemodialysis duration on removal of urea and guanidino compounds: A kinetic analysis." *Nephrol Dial Transpl* 24 (2009): 2225-2232.

How to cite this article: Adam, Teyfon. “Different Drug Level Monitoring in Hemodialysis: A Comprehensive Review.” *J Nephrol Ther* 13 (2023): 452.